<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>262</serviceExecutionTime><Trial id="120604"><TitleDisplay>Atypical antipsychotics for continuation and maintenance treatment after an acute manic episode</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN76555175</Identifier><Identifier type="Secondary Organisational">MCT-53576</Identifier></Identifiers><Indications><Indication id="653">Bipolar disorder</Indication></Indications><BiomarkerNames/><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1034426" type="Company"><TargetEntity id="5000817453" type="organizationId">Canadian Institutes of Health Research</TargetEntity></SourceEntity><SourceEntity id="17414" type="Company"><TargetEntity id="5035554748" type="organizationId">Janssen-Ortho Canada Inc</TargetEntity></SourceEntity><SourceEntity id="17835" type="Company"><TargetEntity id="4296617231" type="organizationId">Eli Lilly Canada Inc</TargetEntity></SourceEntity><SourceEntity id="20532" type="Company"><TargetEntity id="4296804583" type="organizationId">University of British Columbia</TargetEntity></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"/><TargetEntity id="296" type="ICD9"/><TargetEntity id="10057667" type="MEDDRA"/><TargetEntity id="D001714" type="MeSH"/><TargetEntity id="-1667300745" type="omicsDisease"/><TargetEntity id="47" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20532">University of British Columbia</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1034426">Canadian Institutes of Health Research</Company><Company id="17414">Janssen-Ortho Inc (Canada)</Company><Company id="17835">Eli Lilly Canada Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>540</PatientCountEnrollment><DateStart>2002-04-01T00:00:00Z</DateStart><DateEnd type="actual">2007-03-30T00:00:00Z</DateEnd><DateChangeLast>2018-07-18T10:21:14Z</DateChangeLast><DateAdded>2013-04-15T12:46:12Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Mood Disorders CentreUniversity of British Columbia2255 Westbrook Mall, Rm 2C7, Vancouver, British Columbia, V6T 2A1, Canada</Affiliation><Email>yatham@interchange.ubc.ca</Email><Name>Lakshmi Yatham</Name><Phone>1 604 822 7325</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who were recently (within the last 12 weeks) commenced on treatment for a diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) manic or mixed episode with a combination of lithium and&lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt;, lithium and &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt;, or &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Patients who are in remission from mania for at least 2 weeks but no &gt; 6 weeks. Remission is defined as either:&lt;ul&gt;&lt;li&gt;A Clinical Global Impression - severity (CGI-S) scale score of 2 (borderline mentally ill) or less (normal, not ill) for two consecutive weeks&lt;/li&gt;&lt;li&gt;A YMRS score of 8 or less (normal range) and a Hamilton Rating Scale for Depression (HAM-D) 21-item score of 8 or less (normal range) for two consecutive weeks&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Must not be taking any other psychotropic medication with the exception of benzodiazepines (maximum of lorazepam 4 mg per day or its equivalent)&lt;/li&gt;&lt;li&gt;Patients aged &gt;/= 18 years (efficacy of&lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; is not tested in those below 18 years of age), either sex &lt;/li&gt;&lt;li&gt;Patients on 1 to 6 mg&lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or 5 to 25 mg &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; (these are the dose ranges commonly used in clinical practice, and are shown to be effective doses in acute mania trials)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;As we want the findings to be generalisable to clinically representative patients with bipolar disorder, we will not exclude any patients with a history of co-morbid substance abuse or medical illnesses. Any subjects who do not meet the above inclusion criteria will be excluded from the study&lt;/li&gt;&lt;li&gt;Taking any other psychotropic medication with the exception of benzodiazepines (maximum of lorazepam 4 mg per day or its equivalent)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time to any mood episode</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time to premature discontinuation from the study for any clinical reason (dose change in medication, new intervention, side effects, etc)</Description></Measure><Measure><Description>Time to manic episode</Description></Measure><Measure><Description>Time to depressive episode</Description></Measure><Measure><Description>Proportion of patients gaining &gt; 7% of body weight (this amount of weight gain is significant for cardiovascular morbidity)</Description></Measure><Measure><Description>Proportion of patients developing extrapyramidal symptoms, tardive dyskinesia, prolactin related side effects</Description></Measure><Measure><Description>Changes in YMRS, HAM-D 21, CGI-S, ESRS scores and weight during the study period</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the hypothesis, whether continuing &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; for 6 or 12 months (along with a mood stabiliser) would lead to significantly lower rates of relapse or recurrence of mood episodes compared with mood stabiliser monotherapy for 12 months, bipolar patients  are currently in remission but recently treated for an acute manic episode with a mood stabilizer and &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; combination. Continuation of  &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;, plus lithium or valproate for 24 weeks  [&lt;ulink linkType="Reference" linkID="1403240"&gt;1403240&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to one of three groups:&lt;br/&gt;Group A ('0' week group): patients would receive lithium or &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt; plus placebo for 52 weeks (&lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt; tapering would begin on the day of randomization with discontinuation of the drug within 2 weeks).&lt;br/&gt;Group B: continuation of the same atypical antipsychotic, &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;, plus lithium or &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt; for 24 weeks (tapering of the antipsychotic begins at the end of 24 weeks and completed within 2 weeks), followed by the same mood stabiliser plus placebo for another 28 weeks.&lt;br/&gt;Group C: continuation of the atypical antipsychotic, &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3738"&gt;olanzapine&lt;/ulink&gt;, plus lithium or &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt; for 52 weeks. The duration of the double-blind phase of the study would  be 52 weeks and all patients would continue on the mood stabiliser, lithium or &lt;ulink linkType="Drug" linkID="5265"&gt;valproate&lt;/ulink&gt;, they had been on during the acute mania for the full duration of the study [&lt;ulink linkType="Reference" linkID="1403240"&gt;1403240&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Address1>Calgary</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bipolar disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7290">Subjects with Bipolar I Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7296">Subjects with Remission of Bipolar Disorder</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN76555175</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bipolar disorder" id="9921"><Endpoint>Assessment of Bipolar Disorder Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9925">Assessment of time to new episode</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bipolar disorder" id="9921"><Endpoint>Assessment of Bipolar Disorder Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9923">Assessment of mania</SubEndpoint><SubEndpoint disease="Bipolar disorder" id="9925">Assessment of time to new episode</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="9927"><Endpoint>Assessment of Manic Symptoms by Specific Scales</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9932">Assessment by Young Mania Rating Scale (YMRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="9934"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9940">Assessment by Hamilton Depression Rating Scale (HDRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="9968"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9954">Assessment by Clinical Global Impression (CGI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10001"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9922">Assessment of depression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10006"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10025"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10027">Assessment of extra pyramidal symptoms</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="10026"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bipolar disorder" id="5787"><Criterion>Subjects with Bipolar Disorder</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5788">Subjects with bipolar I disorder</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5802"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5803">Subjects with depression</SubCriterion><SubCriterion disease="Bipolar disorder" id="5805">Subjects with mania</SubCriterion><SubCriterion disease="Bipolar disorder" id="5806">Subjects with depression and mania</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5810"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5811">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion><SubCriterion disease="Bipolar disorder" id="5815">Protocol specified scores of Young Mania Rating Scale (YMRS)</SubCriterion><SubCriterion disease="Bipolar disorder" id="5816">Protocol specified scores of Clinical Global Impression Bipolar Illness(CGI-BP)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5822"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5831">Subjects with substance related disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5859"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5862">Subjects with history of antipsychotic therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5883"><Criterion>Subjects with Remission of Bipolar Disorder</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bipolar disorder" id="7488"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7492">Subjects with history of psychotropic agents</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2007-03-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>59.97 Months</EnrollmentPeriod><EnrollmentRate>9.00 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-15T12:46:12Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="121058"><TitleDisplay>The Effect of Dietary Fiber And Protein From Lupin on Blood Glucose in Type 2 Diabetes</TitleDisplay><TitleOfficial>The effect of dietary fiber and protein from lupin on blood glucose in type 2 diabetes</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACTRN12609000375257</Identifier><Identifier type="Other">HREC 2008/185</Identifier><Identifier type="Other">ANZCTR83711</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="6126" role="Therapeutic effect marker" type="Proteomic">Glucagon-like peptide 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lupin dietary fiber-enriched drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lupin protein-enriched drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>soy dietary fiber-enriched drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>soy protein-enriched drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="16842" type="Company"><TargetEntity id="4298537889" type="organizationId">University of Western Australia</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="16842">University of Western Australia</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>33</PatientCountEnrollment><DateStart>2009-05-04T00:00:00Z</DateStart><DateChangeLast>2018-06-13T10:39:15Z</DateChangeLast><DateAdded>2013-04-16T12:01:26Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>School of Medicine and Pharmacology, Medical Research Foundation Building, Perth, Western Australia 6000</Affiliation><Email>Emma.Dove@uwa.edu.au</Email><Name>Emma Dove</Name><Phone>61 8 9224 0341</Phone></Contact><Contact type="Public contact"><Affiliation>School of Medicine and PharmacologyMedical Research Foundation BuildingLevel 4, Rear 50 Murray StreetPERTH Western Australia 6000</Affiliation><Email>Jonathan.Hodgson@uwa.edu.au</Email><Name>Jonathan Hodgson</Name><Phone>61 8 9224 0267</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of type 2 diabetes within the previous ten years (confirmed by a general practitioner, or evident at screening with fasting glucose&amp;gt; 7 mmol/l)&lt;/li&gt;&lt;li&gt;Age 35 to 65 years&lt;/li&gt;&lt;li&gt;Body mass index&amp;lt; 40 kg/m2&lt;/li&gt;&lt;li&gt;Glycated hemoglobin&amp;lt; 9%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Type 1 diabetes&lt;/li&gt;&lt;li&gt;Insulin use&lt;/li&gt;&lt;li&gt;Change in body weight&amp;gt; 10%  in previous 6 months&lt;/li&gt;&lt;li&gt;Smoking currently or within the last 6 months&lt;/li&gt;&lt;li&gt;Daily alcohol consumption&amp;gt; 3 standard drinks for females and &amp;gt; 4 standard drinks for males, known allergy to lupin/nuts/soy/dairy/wheat/gluten&lt;/li&gt;&lt;li&gt;Other major chronic illness&lt;/li&gt;&lt;li&gt;Change in regular medications in previous 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Plasma glucose concentrations assessed using routine biochemical techniques performed in an accredited pathology laboratory</Description><Timeframe>During the 4 h post treatment</Timeframe></Measure><Measure><Description>Plasma insulin concentrations assessed using routine biochemical techniques performed in an accredited pathology laboratory</Description><Timeframe>During the 4 h post treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Incretin hormones including glucagon-like peptide-1 (GLP-1) assessed using a commercially available assay</Description><Timeframe>During the 4 h post treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial was to assess the effect of dietary fiber and protein from lupin on blood glucose in type 2 diabetes and also to  compare glucose and insulin responses following consumption of drinks containing glucose with and without protein and fiber from two different sources: lupin and soy. It was proposed that fiber and protein-enriched drinks (lupin and soy) would be associated with lower postprandial levels of glucose and insulin compared with the carbohydrate-matched control and that the lupin-enriched drink would be associated with lower levels of glucose and insulin compared with the soy-enriched drink [&lt;ulink linkType="Reference" linkID="1403884"&gt;1403884&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either lupin dietary fiber- or  protein-enriched drinks or  soy dietary fiber- or  protein-enriched drinks [&lt;ulink linkType="Reference" linkID="1403884"&gt;1403884&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>Royal Adelaide Hospital</Name><Address1>Adelaide</Address1><Address3> 5000</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="108">Subjects with obesity</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ACTRN12609000375257</Identifier><Identifier>ANZCTR83711</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1354">Mean plasma glucose (MPG)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1377"><Endpoint>Assessment of Incretins</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1380">Total GLP-1 secretion</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="610">Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="849"><Criterion>Subjects  with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="851">Subjects with type 1 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5069">Hypersensitivity/contraindications to any food constituents</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2010-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.90 Months</EnrollmentPeriod><EnrollmentRate>2.37 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-16T12:01:26Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-08-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="206392"><TitleDisplay>PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or II Prostate Cancer</TitleDisplay><TitleOfficial>Analysis of Biopsy Results at 36 Months After Permanent I-125 Implantation Therapy Plus LHRH-agonist Therapy for Patients With Untreated Intermediate Prostate Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00898326</Identifier><Identifier type="Organisational Study">JUSMH-TRIGU0709</Identifier><Identifier type="Secondary Organisational">CDR0000593698</Identifier><Identifier type="Other">SHIP36B</Identifier><Identifier type="Trial Acronym">SHIP36B</Identifier></Identifiers><Indications><Indication id="276">Prostate tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>iodine-125</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>luteinizing hormone releasing-hormone (LHRH) agonist therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1036318" type="Company"><TargetEntity id="5035563736" type="organizationId">Translational Research Informatics Center  Kobe</TargetEntity></SourceEntity><SourceEntity id="21813" type="Company"><TargetEntity id="4298183868" type="organizationId">Jikei University</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="637" type="siCondition"/><TargetEntity id="5083" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1036318">Translational Research Informatics Center, Kobe</Company></CompaniesSponsor><CompaniesCollaborator><Company id="21813">Jikei University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>198</PatientCountEnrollment><DateStart>2011-04-01T00:00:00Z</DateStart><DateEnd type="actual">2016-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-07-02T14:22:05Z</DateChangeLast><DateAdded>2014-07-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Jikei University School of Medicine</Affiliation><Name>Shin Egawa, MD, PhD</Name><Phone>81-3-3437-2370</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically or cytologically confirmed prostate cancer:&lt;ul&gt;&lt;li&gt;Previously untreated disease prior to participation on protocol&lt;ulink linkType="Protocol" linkID="206388"&gt;JUSMH-BRI-GU05-01&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Intermediate-risk disease as defined by the following:&lt;ul&gt;&lt;li&gt;Clinical stage&amp;lt; T2c&lt;/li&gt;&lt;li&gt;Prostate-specific antigen (PSA)&amp;lt;/= 20 ng/ml&lt;/li&gt;&lt;li&gt;Gleason score&amp;lt; 8&lt;/li&gt;&lt;li&gt;Previously enrolled on protocol&lt;ulink linkType="Protocol" linkID="206388"&gt;JUSMH-BRI-GU05-01&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;ECOG performance status 0 to 1&lt;/li&gt;&lt;li&gt;Life expectancy &gt;/= 3 months&lt;/li&gt;&lt;li&gt;WBC &gt;/= 2,000/microl&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 10.0 g/dl&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/microl&lt;/li&gt;&lt;li&gt;Serum creatine level&amp;lt;/= 2.0 mg/dl&lt;/li&gt;&lt;li&gt;ALT and AST&amp;lt;/= 100 IU/l&lt;/li&gt;&lt;li&gt;No other cancer requiring treatment&lt;/li&gt;&lt;li&gt;No poorly controlled hypertension (ie, diastolic blood pressure &gt;/= 120 mmHg)&lt;/li&gt;&lt;li&gt;No severe psychiatric disorders, including schizophrenia or dementia&lt;/li&gt;&lt;li&gt;No poorly controlled diabetes&lt;/li&gt;&lt;li&gt;Considered appropriate for study participation, as determined by the principal investigator or clinical investigator&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;No prior drugs for benign prostatic hyperplasia (other than antiandrogen therapy)&lt;/li&gt;&lt;li&gt;No prior surgery for prostate cancer&lt;/li&gt;&lt;li&gt;No concurrent steroid drugs (except for ointment)&lt;/li&gt;&lt;li&gt;No other concurrent antiandrogen therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Comparison of  PSA levels and biopsy results: compare biobsy results and PSA revels at baseline versus 36 months after brachytherapy</Description><Timeframe>36 to 39 month after PI-125</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This laboratory study was looking at prostate specific antigen (PSA) levels and biopsy samples after undergoing      implant radiation therapy and luteinizing hormone-releasing hormone agonist therapy in      patients with stage I or  II prostate cancer.&lt;/para&gt;&lt;para&gt;The objective was to analyze biopsy results at 36 months after permanent iodine I-125 implantation           therapy and luteinizing hormone-releasing hormone (LHRH) agonist therapy for patients           with untreated intermediate-risk prostate cancer. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who received luteinizing hormone releasing-hormone (LHRH) agonist therapy and      permanent iodine I-125 implantation on protocol &lt;ulink linkType="Protocol" linkID="206388"&gt;JUSMH-BRI-GU05-01&lt;/ulink&gt; would be observed during the study. Patients previously enrolled on protocol JUSMH-BRI-GU05-01 and 36 month after treatement of brachytherapy would be included and observed. Patients would undergo conduct prostatic needle biopsy at 36 to 39 months after brachytherapy. Basic method would be by transectal ultra-sound-guided systematic biopsy; systematic sextant biopsy which involves samples from both seminal vesicles would be adopted as much as possible. Patients would undergo blood sample collection and tissue biopsy for biomarker/laboratory analysis      at 36 months after receiving brachytherapy and releasing-hormone agonist therapy. PSA levels      and biopsy results would be compared.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Jikei University School of Medicine Hospital</Name><Address1>Tokyo</Address1><Address3>125-8506</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3559">Subjects with Early Stage/Localized Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3560">Subjects with Stage I Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3561">Subjects with Stage II Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="17870">Subjects at risk of disease recurrence</PatientSegment><SubSegments><SubSegment id="3567">Subjects with Intermediate Risk of Recurrence</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00898326</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7076"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7081">Assessment of pathological response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3691"><Criterion>Subjects with Stage I Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3692"><Criterion>Subjects with Stage II Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3697"><Criterion>Subjects with Specified Gleason Grade</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3698">Subjects with grade 2 to 4 (low grade)</SubCriterion><SubCriterion disease="Prostate tumor" id="3699">Subjects with grade 5-7 (intermediate grade)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3702"><Criterion>Subjects with Intermediate Risk Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3724"><Criterion>Subjects with acceptable hematological value</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3731"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3732">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3737"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3738">Subjects with ECOG/WHO/Zubrod status 0-2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="7089"><Criterion>Subjects with Early/Localized Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="33310"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3726">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="34007"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3727">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4894"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4966">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4969">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>66.00 Months</EnrollmentPeriod><EnrollmentRate>3.00 Patients/Month</EnrollmentRate><DateFirstReceived>2009-05-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-10-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-07-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="206798"><TitleDisplay>A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnozed Multiple Myeloma</TitleDisplay><TitleOfficial>Phase Ib/II, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnozed Multiple Myeloma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02072863</Identifier><Identifier type="Secondary Organisational">2013-002125-27</Identifier><Identifier type="Organisational Study">OPZ006</Identifier></Identifiers><Indications><Indication id="1828">Multiple myeloma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>melphalan</Name></Intervention><Intervention type="InterventionPrimary"><Name>oprozomib</Name><Drug id="58200">oprozomib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>prednisone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="58200">oprozomib</Drug><IndicationsPioneer/><Companies><Company><Company id="14109">Amgen Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="18683">Onyx Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="58200" type="Drug"><TargetEntity id="462806" type="siDrug">Oprozomib</TargetEntity></SourceEntity><SourceEntity id="14109" type="Company"><TargetEntity id="4295905537" type="organizationId">Amgen Inc</TargetEntity></SourceEntity><SourceEntity id="18683" type="Company"><TargetEntity id="4295907479" type="organizationId">Onyx Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"/><TargetEntity id="10028228" type="MEDDRA"/><TargetEntity id="D009101" type="MeSH"/><TargetEntity id="29073" type="ORPHANET"/><TargetEntity id="-18870694" type="omicsDisease"/><TargetEntity id="710" type="siCondition"/></SourceEntity><SourceEntity id="4917" type="Action"><TargetEntity id="1125" type="Mechanism">Proteasome Inhibitors</TargetEntity><TargetEntity id="3073" type="Mechanism">Immunoproteasome Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>10</NumberOfSites><CompaniesSponsor><Company id="14109">Amgen Inc</Company><Company id="18683">Onyx Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4917">Proteasome inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="80">Peptide</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>9</PatientCountEnrollment><DateStart>2014-01-31T00:00:00Z</DateStart><DateEnd type="actual">2015-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:21:30Z</DateChangeLast><DateAdded>2014-07-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Amgen</Affiliation><Name>MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Newly diagnosed symptomatic multiple myeloma patients who are transplant ineligible with measureable disease as indicated by one or more of the following:&lt;ul&gt;&lt;li&gt;Serum M-protein &gt;/= 500 mg/dl&lt;/li&gt;&lt;li&gt;Urine M-protein &gt;/= 200 mg/24 h&lt;/li&gt;&lt;li&gt;Serum free light chain: involved free light chain (FLC) level &gt;/= 10 mg/dl, provided serum FLC ratio is abnormal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&lt;/li&gt;&lt;li&gt;Creatinine clearance (CrCl) &gt;/= 30 ml/min, either measured or calculated using the formula of Cockcroft and Gault ([140 - age] x mass [kg]/[72 x serum creatinine mg/dl]). Multiply result by 0.85 if female&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any prior systemic anti-myeloma therapy except oral steroids (dexamethasone up to a total dose of 160 mg or equivalent within 14 days prior to the first dose of study treatment is allowed). Use of topical or inhaled steroids is acceptable&lt;/li&gt;&lt;li&gt;Congestive heart failure (New York Hearth Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to first dose&lt;/li&gt;&lt;li&gt;Known or suspected HIV, active hepatitis A, B C or virus infection (exception: patients with chronic or cleared HBV and HCV infection and stable liver function tests [bilirubin, AST] will be allowed)&lt;/li&gt;&lt;li&gt;Significant neuropathy (grade 2 with pain or higher) at the time of first dose&lt;/li&gt;&lt;li&gt;Plasma cell leukemia&lt;/li&gt;&lt;li&gt;POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)&lt;/li&gt;&lt;li&gt;Known amyloidosis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Phase Ib: incidence, nature, and severity of AEs and SAEs of oprozomib, given in combination with melphalan and prednisone</Description><Timeframe>Evaluated at every scheduled study visit</Timeframe></Measure><Measure><Description>Maximum tolerated dose (MTD)- phase Ib: MTD is defined as the highest dose at which a DLT is observed in &lt; 2 of 6 evaluable subjects occurring within the 4 weeks after the first dose of combination therapy</Description><Timeframe>42 weeks</Timeframe></Measure><Measure><Description>Phase II: overall response rate (ORR): ORR defined as a best overall response of sCR, CR, VGPR, or PR according to the IMWG-URC</Description><Timeframe>39 months</Timeframe></Measure><Measure><Description>Complete response rate (CRR)- phase II: CRR defined as a best overall response of sCR or CR according to the IMWG-URC</Description><Timeframe>39 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events (AEs) and serious adverse events (SAEs)- phase II: adverse events (AEs) and serious adverse events (SAEs) graded according to the NCI-CTCAE (Version 4.03)</Description><Timeframe>Collected from signing of informed consent and throughout study until 30 days after the last dose of study treatment (up to 58 weeks)</Timeframe></Measure><Measure><Description>Duration of response (DOR): duration of response (DOR) is defined as the time from evidence of PR or better to disease progression or death due to any cause</Description><Timeframe>39 months</Timeframe></Measure><Measure><Description>Population pharmacokinetic (PK) parameters- apparent clearance and volume of distribution: evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with melphalan and prednisone using a sparse sampling strategy and population-based analysis methodology</Description><Timeframe>Two post-dose time points in cycle 1 day 1, one pre-dose and two post-dose time points on cycle 3 day 1 and cycle 5 day 1</Timeframe></Measure><Measure><Description>Progression-free survival (PFS): progression-free survival is defined as the time from the first day of study treatment (cycle 1 day 1) to the earlier of disease progression or death due to any cause</Description><Timeframe>39 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of phase Ib of the study was to determine the maximum tolerated dose (MTD) of      &lt;ulink linkType="Drug" linkID="58200"&gt;oprozomib&lt;/ulink&gt; in combination with melphalan and prednisone (OMP) and the purpose of Phase II of the study was to estimate the overall response rate (ORR) and complete response rate (CRR) of the OMP combination.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To evaluate the safety and tolerability of oprozomib administered orally in combination with melphalan and prednisone.&lt;br/&gt;To evaluate population PK parameter estimates of oprozomib and variability in these estimates when administered in combination with melphalan and prednisone.&lt;br/&gt;To estimate the duration of response (DOR).&lt;br/&gt;To estimate progression-free survival (PFS).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive combination of &lt;ulink linkType="Drug" linkID="58200"&gt;oprozomib&lt;/ulink&gt; 60 or 120 mg, po, melphalan (9 mg/m2) and prednisone (60 mg/m2) (OMP)po until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of nice cycles (54 weeks), whichever occurs first.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Greece"><Sites><Site><Name>Department of Clinical Therapeutics, University of Athens</Name><Address1>Athens</Address1><Address2>Attica</Address2><CountrySubDivision>Attica</CountrySubDivision><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Medical Monitor</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>AOU Maggiore della Carita, SCDU Heamatology</Name><Address1>Novara</Address1><Contacts/></Site><Site><Name>Azienda Ospedaliera Universitaria S Martino</Name><Address1>Genova</Address1><Contacts/></Site><Site><Name>Hospital City of Health and Science of Turin, Hematology 1 Division</Name><Address1>Turin</Address1><Contacts/></Site><Site><Name>Ospedale Oncologico Regionale</Name><Address1>Rionero in Vulture</Address1><Address2>Potenza</Address2><CountrySubDivision>Potenza</CountrySubDivision><Contacts/></Site><Site><Name>University of Rome</Name><Address1>Rome</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Name>Erasmus MC, Department of Hematology</Name><Address1>Rotterdam</Address1><Contacts/></Site><Site><Name>Vrijc Universiteit Medisch Centrum, Department of Hematology</Name><Address1>Amsterdam</Address1><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Medical Monitor</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Multiple myeloma</Disease><PatientSegments><PatientSegment><PatientSegment id="3870">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3918">Multiple Myeloma Subjects with Specific Eligibility for Stem Cell Therapy</PatientSegment><SubSegments><SubSegment id="3920">Multiple myeloma subjects not eligible for stem cell therapy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02072863</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2013-002125-27</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Multiple myeloma" id="7354"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Multiple myeloma" id="7391"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7372">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Multiple myeloma" id="7373">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Multiple myeloma" id="7488"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7496">Assessment of drug related toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Multiple myeloma" id="7360"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7391"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7393">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7488"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7490">Assessment of serious adverse events (SAE)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7514"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7520"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7523"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Multiple myeloma" id="4601"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Multiple myeloma" id="4627"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4628">Subjects with measurable serum M-protein</SubCriterion><SubCriterion disease="Multiple myeloma" id="4629">Subjects with measurable urine M-protein</SubCriterion><SubCriterion disease="Multiple myeloma" id="4630">Subjects with measurable serum/urine light chain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4690"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4691">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Multiple myeloma" id="4692">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Multiple myeloma" id="4693">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="4735"><Criterion>Subjects with Specific Eligibility for Stem Cell Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4737">Multiple myeloma subjects not eligible for stem cell therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="34054"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4676">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Multiple myeloma" id="6065"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6082"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6083">Subjects with leukemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6089"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6124"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6181"><Criterion>Subjects with Adverse Effects to Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6184">Subjects with drug related toxicity due to myeloma therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.03 Months</EnrollmentPeriod><EnrollmentRate>0.69 Patients/Month</EnrollmentRate><DateFirstReceived>2014-02-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-11-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="231536"><TitleDisplay>Study of Injection of Follicular Fluid into Uterine Cavity on Implantation Rate in IVF Cycle</TitleDisplay><TitleOfficial>Study of Injection of Follicular Fluid into Uterine Cavity on Implantation Rate in IVF Cycle</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2015021713566N3</Identifier><Identifier type="Secondary Organisational">TBZMED.REC.1394.129</Identifier></Identifiers><Indications><Indication id="1080">Female infertility</Indication></Indications><BiomarkerNames><BiomarkerName id="68" role="Therapeutic effect marker" type="Genomic;Proteomic">Choriogonadotropin subunit beta</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>follicular fluid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25107" type="Company"><TargetEntity id="5035529437" type="organizationId">Tabriz University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="1080" type="ciIndication"><TargetEntity id="N97" type="ICD10"/><TargetEntity id="628" type="ICD9"/><TargetEntity id="10021928" type="MEDDRA"/><TargetEntity id="D007247" type="MeSH"/><TargetEntity id="-932722270" type="omicsDisease"/><TargetEntity id="553" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25107">Tabriz University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>110</PatientCountEnrollment><DateStart>2015-04-19T00:00:00Z</DateStart><DateChangeLast>2018-01-29T22:06:03Z</DateChangeLast><DateAdded>2007-07-19T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Tabriz University of Medical Sciences</Affiliation><Email>hamdik@tbzmed.ac.ir; lahroudin@gmail.com</Email><Name>Dr. Kobra Hamdi</Name><Phone>00984135569543 00989143135851</Phone></Contact><Contact type="Public contact"><Affiliation>Tabriz University of Medical Sciences</Affiliation><Email>hamdik@tbzmed.ac.ir; lahroudin@gmail.com</Email><Name>Dr. Kobra Hamdi</Name><Phone>00984135569543 00989143135851</Phone></Contact><Contact type="Public contact"><Affiliation>Tabriz University of Medical Sciences</Affiliation><Email>hamdik@tbzmed.ac.ir</Email><Name>Dr. Kobra Hamdi</Name><Phone>00984135539161 00989143135851</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients aged 20 to 40 years old&lt;/li&gt;&lt;li&gt;FSH levels&amp;lt; 10 mIU/ml&lt;/li&gt;&lt;li&gt;BMI&amp;lt; 35 kg /m2&lt;/li&gt;&lt;li&gt;Transfer two or  three embryos Grade A or B&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with endometriosis, hydrosalpinx, uterine anatomical abnormalities such as myoma, polyps, mullerian anomalies like two horns of the uterus, endocrine disorders such as thyroid disease, PCO and have a history of two or more implantation failure&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Chemical pregnancy: hCG test</Description><Timeframe>Measure beta-HCG 16 days after injection of HCG</Timeframe></Measure><Measure><Description>Clinical pregnancy (gestational sac seen by viewing the fetal heart rate and fetal pole): ultrasound</Description><Timeframe>After positive beta-hCG</Timeframe></Measure><Measure><Description>Implantation rates: ultrasound</Description><Timeframe>2 weeks after a positive pregnancy test</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of this study is  to evaluate the effects of  injecting follicular fluid into uterine cavity on implantation rate in in-vitro fertilization (IVF) cycle. In this study, the primary outcome is successful implantation and clinical pregnancy is considered to be a secondary consequence.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In a randomized unit-central clinical trial, 68 patients with recurrent implantation failure referring to infertility clinic of Alzahra Hospital, Tabriz, Iran, will be randomly assigned to two groups' case and control. Patients will be randomly placed in two groups of 55 patients. From day 2 or 3, cycles of 150 to 300 IU FSH injection and ovulation induction will start. After six or seven cycles, antagonist of GnRH injections will be administered at a dose of 250 mg daily and 75 to 150 units monogon will be added to the diet (one to two tablets). After  at least three follicles &amp;gt; 18 mm, HCG will be injected and then 34 to 36 h after that,   puncture of ovarian follicles will be done. The follicular fluid of two or three follicular puncture will be obtained; if that is not tinged with blood,  it will be centrifuged and collected in a separate tube, after removal of the oocyte. After puncture 2 cc of the liquid will be injected into the uterus using IUI catheters. Embryo transfer will take place 2 days after ovarian puncture.&lt;br/&gt;In the control group, the method is the same  without injected follicular liquid.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Alzahra Hospital</Name><Address1>Tabriz</Address1><Address2>East Azerbayjan</Address2><CountrySubDivision>East Azerbayjan</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr. Kobra Hamdi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Infertility</Disease><PatientSegments><PatientSegment><PatientSegment id="11671">Subjects with Histroy of Infertility</PatientSegment><SubSegments><SubSegment id="11672">Women with infertility</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11680">Subjects with Assisted Reproductive Technique(ART)</PatientSegment><SubSegments><SubSegment id="11681">Women with in vitro fertilisation(IVF)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11684">Subjects with Assisted Reproductive Technique(ART) Failure</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2015021713566N3</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Infertility" id="23236"><Endpoint>Assessment of Embryo</Endpoint><SubEndpoints><SubEndpoint disease="Infertility" id="23239">Assessment of embryo implantation rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Infertility" id="23245"><Endpoint>Assessment of Pregnancy</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Infertility" id="21052"><Criterion>Subjects with History of Infertility</Criterion><SubCriteria><SubCriterion disease="Infertility" id="21053">Women with a history of infertility</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Infertility" id="21067"><Criterion>Subjects with protocol Specified Hormonal Levels</Criterion><SubCriteria><SubCriterion disease="Infertility" id="21068">Subjects with protocol specified FSH levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Infertility" id="21070"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Infertility" id="21072"><Criterion>Subjects with Assisted Reproductive Technique(ART)</Criterion><SubCriteria><SubCriterion disease="Infertility" id="21073">Women with in vitro fertilisation(IVF)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Infertility" id="21076"><Criterion>Subjects with Assisted Reproductive Technique(ART) Failure</Criterion></Inclusion><Inclusion disease="Infertility" id="21079"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Infertility" id="17968"><Criterion>Subjects co-morbid with genitourinary disorders</Criterion></Exclusion><Exclusion disease="Infertility" id="17977"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Infertility" id="17982"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Infertility" id="18003"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>15.42 Months</EnrollmentPeriod><EnrollmentRate>7.13 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="updated"><Date>2017-07-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="added"><Date>2007-07-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="299850"><TitleDisplay>A Phase III, Double-Blind, Two-Arm Study in the Treatment of Acne Vulgaris</TitleDisplay><TitleOfficial>A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Two-Arm, Parallel-Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03168321</Identifier><Identifier type="Organisational Study">V01-123A-301</Identifier></Identifiers><Indications><Indication id="3040">Acne vulgaris</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tazarotene (low-concentration lotion, acne/psoriasis), Bausch Health</Name><Drug id="98805">tazarotene (low-concentration lotion, acne/psoriasis), Bausch Health</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="98805">tazarotene (low-concentration lotion, acne/psoriasis), Bausch Health</Drug><IndicationsPioneer/><Companies><Company><Company id="17058">Bausch Health Companies Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17058" type="Company"><TargetEntity id="4295861031" type="organizationId">Valeant Pharmaceuticals International Inc</TargetEntity></SourceEntity><SourceEntity id="3040" type="ciIndication"><TargetEntity id="L70.0" type="ICD10"/><TargetEntity id="706.1" type="ICD9"/><TargetEntity id="D000152" type="MeSH"/><TargetEntity id="-1958569535" type="omicsDisease"/><TargetEntity id="3883" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>44</NumberOfSites><CompaniesSponsor><Company id="17058">Bausch Health Companies Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1880">Dermatological agent</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>813</PatientCountEnrollment><DateStart>2017-06-29T00:00:00Z</DateStart><DateEnd type="actual">2018-09-05T00:00:00Z</DateEnd><DateChangeLast>2019-05-20T11:07:51Z</DateChangeLast><DateAdded>2017-05-31T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Valeant Pharmaceuticals</Affiliation><Name>Anya Loncaric</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female at least &gt;/= 9 years of age&lt;/li&gt;&lt;li&gt;Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit)&lt;/li&gt;&lt;li&gt;Subject must have a score of 3 (moderate) or 4 (severe) on the evaluator's global severity assessment at the baseline visit&lt;/li&gt;&lt;li&gt;Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no&amp;lt; 20 but no &gt; 50&lt;/li&gt;&lt;li&gt;Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no&amp;lt; 25 but no &gt; 100&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study&lt;/li&gt;&lt;li&gt;Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema&lt;/li&gt;&lt;li&gt;Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive&lt;/li&gt;&lt;li&gt;Subjects with a facial beard or mustache that could interfere with the study assessments&lt;/li&gt;&lt;li&gt;Subjects with more than two  facial nodules&lt;/li&gt;&lt;li&gt;Evidence or history of cosmetic-related acne&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Absolute change in mean inflammatory lesion counts: superiority in absolute change from baseline to week 12 in mean inflammatory lesion counts</Description><Timeframe>Baseline to week 12</Timeframe></Measure><Measure><Description>Percent of patients who achieve at least a two-grade reduction in the Evaluator's Global Severity Score: percent of patients who achieve at least a two-grade reduction from baseline and are clear or almost clear at week 12 in the evaluator's global severity score</Description><Timeframe>Baseline to week 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a multicenter, randomized, double-blind, vehicle-controlled study designed to assess      the safety, efficacy, and tolerability of &lt;ulink linkType="Drug" linkID="98805"&gt;IDP-123&lt;/ulink&gt; lotion in comparison with IDP-123 vehicle      lotion.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either IDP-123 lotion or IDP-123 vehicle lotion.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Valeant Site 10</Name><Address1>Laval</Address1><Address2>Quebec</Address2><Address3>H7E0E3</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 28</Name><Address1>Waterloo</Address1><Address2>Ontario</Address2><Address3>N2J1C4</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 29</Name><Address1>Peterborough</Address1><Address2>Ontario</Address2><Address3>K9J5K2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Valeant Site 01</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>22434</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 02</Name><Address1>Manhattan Beach</Address1><Address2>California</Address2><Address3>90266</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 03</Name><Address1>West Palm Beach</Address1><Address2>Florida</Address2><Address3>33401</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 04</Name><Address1>La Mesa</Address1><Address2>California</Address2><Address3>91942</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 05</Name><Address1>Katy</Address1><Address2>Texas</Address2><Address3>77494</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 06</Name><Address1>Arlington Heights</Address1><Address2>Illinois</Address2><Address3>60005</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 08</Name><Address1>Metairie</Address1><Address2>Louisiana</Address2><Address3>70006</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 09</Name><Address1>High Point</Address1><Address2>North Carolina</Address2><Address3>27262</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 11</Name><Address1>Dublin</Address1><Address2>Ohio</Address2><Address3>43016</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 12</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78759</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 13</Name><Address1>Sanford</Address1><Address2>Florida</Address2><Address3>32771</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 15</Name><Address1>Johnston</Address1><Address2>Rhode Island</Address2><Address3>02919</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 16</Name><Address1>Warren</Address1><Address2>Michigan</Address2><Address3>48088</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 17</Name><Address1>South Bend</Address1><Address2>Indiana</Address2><Address3>46617</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 18</Name><Address1>Plano</Address1><Address2>Texas</Address2><Address3>75093</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 19</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85032</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 21</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85032</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 22</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40217</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 23</Name><Address1>New Albany</Address1><Address2>Indiana</Address2><Address3>47150</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 24</Name><Address1>Hot Springs</Address1><Address2>Arkansas</Address2><Address3>71913</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 25</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78213</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 26</Name><Address1>Newnan</Address1><Address2>Georgia</Address2><Address3>30263</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 27</Name><Address1>Pembroke Pines</Address1><Address2>Florida</Address2><Address3>33028</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 30</Name><Address1>Boise</Address1><Address2>Idaho</Address2><Address3>83704</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 31</Name><Address1>Overland Park</Address1><Address2>Kansas</Address2><Address3>66215</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 32</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45236</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 33</Name><Address1>Ormond Beach</Address1><Address2>Florida</Address2><Address3>32174</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 34</Name><Address1>Knoxville</Address1><Address2>Tennessee</Address2><Address3>37917</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 35</Name><Address1>Boca Raton</Address1><Address2>Florida</Address2><Address3>33486</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 36</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10075</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 37</Name><Address1>Wheat Ridge</Address1><Address2>Colorado</Address2><Address3>80033</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 38</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3>48202</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 39</Name><Address1>Sacramento</Address1><Address2>California</Address2><Address3>95819</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 40</Name><Address1>North Miami Beach</Address1><Address2>Florida</Address2><Address3>33162</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 41</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84114</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 42</Name><Address1>Murrieta</Address1><Address2>California</Address2><Address3>92562</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 43</Name><Address1>Webster</Address1><Address2>Texas</Address2><Address3>77598</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 44</Name><Address1>Spokane</Address1><Address2>Washington</Address2><Address3>99202</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Valeant Site 45</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23507</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Valeant site 20</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10022</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>valeant Site 07</Name><Address1>Gresham</Address1><Address2>Oregon</Address2><Address3>97030</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts/></Site><Site><Name>valeant Site 14</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37215</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Acne vulgaris</Disease><PatientSegments><PatientSegment><PatientSegment id="9208">Subjects with Inflammatory Lesions</PatientSegment><SubSegments><SubSegment id="9209">Subjects with papules</SubSegment><SubSegment id="9210">Subjects with pustules</SubSegment><SubSegment id="9211">Subjects with nodules/nodulocystic lesions</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9212">Subjects with Non-inflammatory Lesions</PatientSegment><SubSegments><SubSegment id="9213">Subjects with open/closed comedones</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19890">Subjects by disease severity</PatientSegment><SubSegments><SubSegment id="9204">Subjects with Moderate Acne Vulgaris</SubSegment><SubSegment id="9205">Subjects with Severe Acne Vulgaris</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03168321</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Acne vulgaris" id="16154"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Acne vulgaris" id="22291"><Endpoint>Assessment of Lesion Count and Characteristics</Endpoint><SubEndpoints><SubEndpoint disease="Acne vulgaris" id="16146">Change in inflammatory lesion counts</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Acne vulgaris" id="16157"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Acne vulgaris" id="14976"><Criterion>Subjects with Inflammatory Lesions</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14977">Subjects with papules</SubCriterion><SubCriterion disease="Acne vulgaris" id="14978">Subjects with pustules</SubCriterion><SubCriterion disease="Acne vulgaris" id="14979">Subjects with nodules/nodulocystic lesions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acne vulgaris" id="14980"><Criterion>Subjects with Non-inflammatory Lesions</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14981">Subjects with open/closed comedones</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acne vulgaris" id="33270"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14969">Subjects with Moderate Acne Vulgaris</SubCriterion><SubCriterion disease="Acne vulgaris" id="14970">Subjects with Severe Acne Vulgaris</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acne vulgaris" id="34414"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14984">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acne vulgaris" id="34472"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="33230">Subjects with protocol specified Investigator Global Assessment (IGA) scores</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acne vulgaris" id="34800"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14986">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Acne vulgaris" id="12440"><Criterion>Subjects with Other Forms of Acne</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="12441">Subjects with acne fulminans/acne congoblata</SubCriterion><SubCriterion disease="Acne vulgaris" id="12442">Subjects with secondary acne</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acne vulgaris" id="12445"><Criterion>Subjects with Skin &amp; Connective Tissue Disorders</Criterion></Exclusion><Exclusion disease="Acne vulgaris" id="12470"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="12478">Subjects with history of investigative product use</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acne vulgaris" id="12485"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="14159">Subjects with history of usage of cosmetics/skin care products</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acne vulgaris" id="25413"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="13591">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acne vulgaris" id="26719"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Acne vulgaris" id="12490">Subjects unlikely/unable to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-03-16T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.10 Months</EnrollmentPeriod><EnrollmentRate>89.34 Patients/Month</EnrollmentRate><DateFirstReceived>2017-05-24T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-04-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="300179"><TitleDisplay>The Effect Of Melatonin On Patients With Hemorrhagic Stroke</TitleDisplay><TitleOfficial>The Benefit Of Melatonin On Damage Associated Molecular Pattern Following Hemorrhagic Stroke Patients Under Mechanical Ventilation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2016100530164N1</Identifier><Identifier type="Secondary Organisational">IR.TUMS.VCR.REC.1395.884</Identifier></Identifiers><Indications><Indication id="3677">Hemorrhagic stroke</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="540" role="Therapeutic effect marker" type="Genomic;Proteomic">Protein S100-B</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>melatonin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="3677" type="ciIndication"><TargetEntity id="10019016" type="MEDDRA"/><TargetEntity id="95" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2016-12-06T00:00:00Z</DateStart><DateChangeLast>2017-06-05T16:00:37Z</DateChangeLast><DateAdded>2017-06-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tehran university of medical sience</Affiliation><Email>mehrnoush.dianatkhah@gmail.com</Email><Name>Mehrnoush Dianatkhah</Name><Phone>00982164122130</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tehran university of medical sience</Affiliation><Email>mehrnoush.dianatkhah@gmail.com</Email><Name>Mehrnoush Dianatkhah</Name><Phone>00982164122130 00</Phone></Contact><Contact type="Public contact"><Affiliation>Tehran university of medical sience</Affiliation><Email>Mehrnoush.dianatkhah@gmail.com</Email><Name>Mehrnoush Dianatkhah</Name><Phone>00982164122130 00</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with hemorrhagic stroke who have been admitted within 72 h after stroke&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Liver failure (liver enzymes more than 3 fold)&lt;/li&gt;&lt;li&gt;Renal failure (GFR&amp;lt; 60)&lt;/li&gt;&lt;li&gt;Patients with brain tumor&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>S100B: laboratory Kit</Description><Timeframe>Before intervention and 5 days after initiation of intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>GCS: GCS evaluating score</Description><Timeframe>Before the intervetion and 5 days after initiation of intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective is to evaluate the neuroprotective effect of melatonin on hemorrhagic stroke.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be a randomized, double-blind study. Total 40  adult patients with acute ICH who are admitted to the ICU within 72 h of onset will be enrolled. After singing a written consent, patients will be randomized to receive either melatonin or be in the control group. Patients in the melatonin group will receive 30 mg of melatonin every night throughout nasogastric tube for 5 days. Control group will not receive any intervention. Blood samples will be drawn from all patients and store 70degC until analyzed.&lt;/para&gt;&lt;para&gt;Main outcome variables: In order to measure the severity of clinical neurological defect, the Glasgow Coma Score (GCS) will be assessed at baseline and then daily for 5 days. S100B and CRP as a biomarker of neuronal injury will be assessed once on day 1 and 5 post ICU admission.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Sina hospital (ICU ward)</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><Address3>11367-46911</Address3><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Mehrnoush Dianatkhah</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11630">Subjects with Hemorrhagic Stroke</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2016100530164N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="44115"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24265">Assessment of S100 proteins</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Stroke" id="24210"><Endpoint>Assessment of Other Events</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24211">Assessment of neurological events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Stroke" id="24235"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24237">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20936"><Criterion>Stroke Subjects</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20937">Subjects with hemorrhagic stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20957"><Criterion>Inclusion Based on Time Post Stroke</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18642"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Stroke" id="18643"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Stroke" id="18662"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stroke" id="18686"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18687">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-03-08T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.10 Months</EnrollmentPeriod><EnrollmentRate>12.90 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="50349"><TitleDisplay>Sativex for Treatment of Chemotherapy Induced Neuropathic Pain</TitleDisplay><TitleOfficial>A Double-Blind, Placebo-Controlled, Crossover,  Pilot Trial of Sativex With Open-Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CDHA-RS/2009-316</Identifier><Identifier type="NCT">NCT00872144</Identifier></Identifiers><Indications><Indication id="1295">Neuropathic pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nabiximols, GW Pharmaceuticals</Name><Drug id="21503">nabiximols, GW Pharmaceuticals</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="21503">nabiximols, GW Pharmaceuticals</Drug><IndicationsPioneer/><Companies><Company><Company id="1038853">Capital District Health Authority</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="21503" type="Drug"><TargetEntity id="137794" type="siDrug">THC</TargetEntity><TargetEntity id="307043" type="siDrug">Nabiximols</TargetEntity></SourceEntity><SourceEntity id="1038853" type="Company"><TargetEntity id="4298147419" type="organizationId">Capital District Health Authority</TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"/><TargetEntity id="D009437" type="MeSH"/><TargetEntity id="-533466818" type="omicsDisease"/><TargetEntity id="14" type="siCondition"/></SourceEntity><SourceEntity id="2577" type="Action"><TargetEntity id="1986" type="Mechanism">Cannabinoid CB1 Receptor Ligands</TargetEntity><TargetEntity id="5365" type="Mechanism">Cannabinoid CB1 Allosteric Modulators</TargetEntity><TargetEntity id="5366" type="Mechanism">Cannabinoid CB1 Modulators</TargetEntity></SourceEntity><SourceEntity id="2578" type="Action"><TargetEntity id="1987" type="Mechanism">Cannabinoid CB2 Receptor Ligands</TargetEntity><TargetEntity id="3605" type="Mechanism">Cannabinoid CB2 Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1038853">Capital District Health Authority</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2577">Cannabinoid CB1 receptor modulator</Action><Action id="2578">Cannabinoid CB2 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2946">Analgesic</Class><Class id="5557">Muscle relaxant</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="175">Drug combination</Technology><Technology id="897">Formulation aerosol</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><PatientCountEvaluable>16</PatientCountEvaluable><DateStart>2010-06-30T00:00:00Z</DateStart><DateEnd type="actual">2013-03-01T00:00:00Z</DateEnd><DateChangeLast>2018-07-07T04:01:27Z</DateChangeLast><DateAdded>2009-04-01T08:56:36Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Capital District Health Authority, Canada</Affiliation><Name>Mary E Lynch, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Neuropathic pain beginning after chemotherapy with paclitaxil, vincristine or             cis-platin that has been present for 3 months or longer&lt;/li&gt;&lt;li&gt;Presence of allodynia, hyperalgesia or hypoesthesia on sensory testing in the area of             pain-Moderate to severe pain, as defined by an average 7-day pain score &gt; 4.0             on an 11-point numerical rating scale for pain intensity (NRS-PI) &lt;/li&gt;&lt;li&gt;Medications must have been stable for at least 14 days&lt;/li&gt;&lt;li&gt;Ability to follow the protocol&lt;/li&gt;&lt;li&gt;Willing and able to give written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Ischemic heart disease&lt;/li&gt;&lt;li&gt;Personal history of schizophrenia or psychotic disorder&lt;/li&gt;&lt;li&gt;Family history of schizophrenia or psychotic disorder in first degree family member             (parent, sibling or child)&lt;/li&gt;&lt;li&gt;Allergy to cannabinoids&lt;/li&gt;&lt;li&gt;Presence of any other clinically significant medical disorder (other than the cancer             requiring chemotherapy) on history or physical exam that would compromise the             participants safety in the trial as judged by the study physician&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in the NRS-PI from baseline to the final week of stable dose treatment)</Description><Timeframe>Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)</Timeframe></Measure><Measure><Description>Participants gaining a 30% or greater reduction in the NRS-PI</Description><Timeframe>Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Secondary outcome measures will include measures in the remaining domains (suggested by IMMPACT). These include SF36, Quantitative sensory examination, Global Impression of Change, PGIC and Patient Satisfaction Scale, PSS</Description><Timeframe>After stable dosing is achieved (week 3)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This purpose of this study  was to examine the effect of a cannabinoid extract      (&lt;ulink linkType="Drug" linkID="21503"&gt;Sativex&lt;/ulink&gt;) in treatment of neuropathic pain caused by chemotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in January 2014. When examining the whole group, no statistically significant difference was observed between the treatment and the placebo groups on the NRS-PI. A responder analysis demonstrated that a two-point or greater reduction in pain was observed in five participants who reported  that trended toward statistical significance and the number needed to treat was five  [&lt;ulink linkType="Reference" linkID="1532971"&gt;1532971&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The problem of neuropathic pain: A recent review has identified a neuropathic pain prevalence rate of 2-3% in the general population 1. Based on a Canadian population of 30 million, this means that close to one million Canadians suffer with neuropathic pain. Neuropathic pain was one of the most difficult types of persistent pain to treat effectively. No more than 50% 2 of patients with neuropathic pain obtain adequate relief using current treatments. This was related to the fact that there were numerous pathophysiological mechanisms that contribute to neuropathic pain. Neuropathic pain was now understood to involve neural responses in which both peripheral and central mechanisms contribute to the generation of spontaneous pain and evoked aspects including allodynia and hyperalgesia 3 to 5, Traditional approaches to neuropathic pain have involved the use of oral medications as single agents or in combination (NSAIDs, opioids, anticonvulsants, tricyclic type antidepressants) 6,7. Unfortunately this approach was often inadequate and accompanied by side effects. New treatments were needed for management of neuropathic pain Neuropathic pain associated with chemotherapy: Neuropathic pain associated with chemotherapy used for treatment of solid tumors (eg. paclitaxil, vincristine and cis-platin) was particularly resistant to treatment and was a growing clinical problem as chemotherapeutic regimes grow more successful in extending life. This type of neuropathic pain was particularly resistant to treatment and contributes to the overall level of suffering experienced by patients who recovering from cancer treatment with chemotherapy. There was pre-clinical evidence supporting that cannabinoid agonists may be helpful for treatment neuropathic pain caused by chemotherapy. Cannabinoids in treatment of pain: The potent anti-nociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain, the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery and evidence supporting endogenous modulation of pain systems by cannabinoids, provide support that cannabinoids exhibit significant potential as analgesics8-13. In addition sixteen of 19 randomized controlled trials examining cannabinoids in the treatment of pain have demonstrated a significant analgesic effect , nine of the positive trials involved neuropathic pain 14. Several of these trials examined a cannabinoid extract preparation &lt;ulink linkType="Drug" linkID="21503"&gt;Sativex&lt;/ulink&gt;15 to 20 proposed in the current trial. What was the current standard of care for neuropathic pain caused by chemotherapy? The current standard of care for neuropathic pain associated with chemotherapy was similar to that for management of chronic neuropathic pain. The approach consists of an interdisciplinary active participatory approach to living with incurable pain. This includes trials of pharmacotherapy (eg. anti-convulsant analgesics, tricyclic antidepressant analgesics and opioids), therapeutic exercise programs and training in coping strategies such as pacing and positive self talk. Such an approach was offered at multidisciplinary pain centres such as the Pain Management Unit (PMU) here at CDHA. Study question: Given the limitations of current best practice, the compelling pre-clinical work supporting that cannabinoids exhibit anti-nociceptive effects in neuropathic pain and more specifically in chemotherapy induced neuropathic pain and initial clinical trials supporting that &lt;ulink linkType="Drug" linkID="21503"&gt;Sativex&lt;/ulink&gt; exhibits efficacy in other types of neuropathic pain we propose a pilot trial of 30 patient to evaluate the effectiveness of &lt;ulink linkType="Drug" linkID="21503"&gt;Sativex&lt;/ulink&gt; in treatment of neuropathic pain caused by chemotherapy. If there were positive therapeutic effects in the pilot trial, we plan a subsequent randomized controlled trial.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Queen Elizabeth II Health Sciences Centre, Pain Management Unit</Name><Address1>Halifax</Address1><Address2>Nova Scotia</Address2><Address3>B3H 2Y9</Address3><CountrySubDivision>Nova Scotia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="8977">Cancer/Treatment-related Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8389">Subjects with Moderate to Severe Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8390">Subjects with Neuropathic Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00872144</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19282"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19411"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19412">Assessment of Other Treatment or Procedure Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19428"><Endpoint>Assessment of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19429">Numerical Rating Scale (NRS-11, NRS-101)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25895">Rate of &gt;/=30% response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="26820">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Solid tumor" id="26849">Assessment by Patient Satisfaction Scale</SubEndpoint><SubEndpoint disease="Solid tumor" id="26851">Assessment of Patient Global Impression of Change (PGIC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19282"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19312">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Cancer supportive care" id="32210">Assessment of Patient Global Impression of Change (PGIC)</SubEndpoint><SubEndpoint disease="Cancer supportive care" id="37111">Assessment by Patient Satisfaction Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25982"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25985">Assessment by Clinical Global Impression (CGI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26005">Quantitative sensory testing</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25986">Assessment by Patient Global Impression Scale (PGI)</SubEndpoint><SubEndpoint disease="Pain" id="34812">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13120"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13355">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Cancer supportive care" id="13359">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13393"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22090">Subjects with chronic pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22091"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Pain" id="22093">Subjects with moderate pain</SubCriterion><SubCriterion disease="Pain" id="22094">Subjects with severe pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22096"><Criterion>Subjects with Neuropathic Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22144"><Criterion>Subjects with Cancer Related Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22150">Based on Numerical Rating Scale [NRS]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22191">Subjects with central nervous system disease/disorder associated pain</SubCriterion><SubCriterion disease="Pain" id="22206">Subjects with malignancy associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22253">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="22235">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="33243"><Criterion>Subjects with disease complications</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13306">Subjects with cancer/treatment-related pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34403"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13377">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="34876"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13379">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10723"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10900"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10908"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10909">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.06 Months</EnrollmentPeriod><EnrollmentRate>0.55 Patients/Month</EnrollmentRate><DateFirstReceived>2009-03-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-04-01T08:56:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-03-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2014-03-10T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="60783"><TitleDisplay>A Study To Evaluate the Long-Term, Safety, Tolerability and Effect on Disease Course</TitleDisplay><TitleOfficial>A Multinational, Multicenter, Open-label, Single-assignment, Extension of the MS-LAQ-301 Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily po Laquinimod 0.6 mg in Subjects With Relapsing MS</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MS-LAQ-301E</Identifier><Identifier type="NCT">NCT00988052</Identifier><Identifier type="Secondary Organisational">2009-012989-30</Identifier><Identifier type="Trial Acronym">ALLEGRO Extension</Identifier></Identifiers><Indications><Indication id="213">Multiple sclerosis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Toxic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="125" role="Toxic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="177" role="Toxic effect marker" type="Genomic;Proteomic">Fibrinogen</BiomarkerName><BiomarkerName id="213" role="Toxic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="330" role="Toxic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Toxic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="1211" role="Toxic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="1236" role="Toxic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2054" role="Toxic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="2098" role="Toxic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2527" role="Toxic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="8024" role="Toxic effect marker" type="Genomic;Proteomic">Creatine kinase</BiomarkerName><BiomarkerName id="8458" role="Toxic effect marker" type="Genomic;Proteomic">gamma-Glutamyltransferase</BiomarkerName><BiomarkerName id="18315" role="Therapeutic effect marker" type="Physiological">Visual acuity</BiomarkerName><BiomarkerName id="28899" role="Toxic effect marker" type="Genomic;Proteomic">Alkaline phosphatase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laquinimod</Name><Drug id="25049">laquinimod</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="25049">laquinimod</Drug><IndicationsPioneer/><Companies><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="25049" type="Drug"><TargetEntity id="282472" type="siDrug">Laquinimod sodium</TargetEntity></SourceEntity><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity><SourceEntity id="11774" type="Action"><TargetEntity id="2308" type="Mechanism">Aryl Hydrocarbon Receptor (AhR) Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason><Reason>Other</Reason></ReasonForTrialDiscontinuation><NumberOfSites>146</NumberOfSites><CompaniesSponsor><Company id="20348">Teva Pharmaceutical Industries Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11774">Aryl hydrocarbon receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1589">Apoptosis stimulator</Class><Class id="1596">Immunomodulator</Class><Class id="1615">Neuroprotectant</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>839</PatientCountEnrollment><PatientCountEvaluable>864</PatientCountEvaluable><DateStart>2009-11-10T00:00:00Z</DateStart><DateEnd type="actual">2017-07-01T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T17:35:59Z</DateChangeLast><DateAdded>2009-10-06T08:45:49Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>U.O.Neurology-Neurorehabilitation and Clinical Neurophysiology</Affiliation><Name>Giancarlo Comi, Prof., MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have   completed the termination visit of    MS-LAQ-301 study(completion of all termination visit activities) according to the MS-LAQ-301 protocol&lt;/li&gt;&lt;li&gt;Women of childbearing potential(for example women who are notpostmenopausal or surgically sterilized) must practice an acceptable method of birth control (acceptable methods of birth control in this open label extension phase include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch [or hormone-releasing vaginal ring], long-acting injectable contraceptive, partner's vasectomy or double-barrier method [condom or diaphragm with spermicide]) during the study and up to 30 days after the last dose of the study drug&lt;/li&gt;&lt;li&gt;Patients must be willing and able to comply with the protocol requirements for the duration of the study&lt;/li&gt;&lt;li&gt;Patients must be able to comprehend, sign and date a written informed consent prior to entering the MS-LAQ-301E study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Premature discontinuation from the MS-LAQ-301 study, for any reason&lt;/li&gt;&lt;li&gt;Pregnancy (according to urine dipstick beta-HCG test performed at baseline [month 0E] visit) or breastfeeding&lt;/li&gt;&lt;li&gt;Patients with clinically significant or unstable medical or surgical condition detected or worsened during the MS-LAQ-301 study, which preclude safe participation and completion of the MS-LAQ-301E study. Acute exacerbation of MS will not exclude participation in the MS-LAQ-301E study&lt;/li&gt;&lt;li&gt;Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, month 0E)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Participants With Treatment-Emergent Adverse Events (TEAEs): a treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest</Description><Timeframe>Day 1 up to 7.64 years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Proportion of subjects (%) who prematurely discontinued from the study due to AEs and the time to withdrawal</Description></Measure><Measure><Description>Participants With Potentially Clinically Significant Abnormal Vital Signs: vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria: Pulse rate low: &lt;=45 and decrease &gt;=30 beats/minute; Pulse rate high: &gt;=120 and increase &gt;=30 beats/minute; Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg; Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg; Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg; Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg</Description><Timeframe>Day 1 up to 7.64 years</Timeframe></Measure><Measure><Description>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study: counts include two conditions: a change from High / Non-PCS at baseline to Low PCS at any point during the study; a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count. ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</Description><Timeframe>Day 1 up to 7.64 years</Timeframe></Measure><Measure><Description>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study: counts include two conditions: a change from High / Non-PCS at baseline to Low PCS at any point during the study; a change from Low / Non-PCS at baseline to High PCS at any point during the study Participants whose condition was not changed from baseline or was changed to a non- PCS value are included in the population count</Description><Timeframe>Day 1 up to 7.64 years</Timeframe></Measure><Measure><Description>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study: shifts are presented as Baseline finding / Worse finding at anytime during the study. Categories for findings are: normal; abnormal, not clinically significant (Not CS); abnormal, clinically significant (CS)</Description><Timeframe>Day 1 up to 7.64 years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;&gt;In March 2013, results were presented. A favorable safety and tolerability profile of &lt;ulink linkType="Drug" linkID="25049"&gt;laquinimod&lt;/ulink&gt; was reported. There were no new safety concerns reported during the extension phase [&lt;ulink linkType="Reference" linkID="1394350"&gt;1394350&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the pooled results of ALLEGRO EXTENSION, &lt;ulink linkType="Protocol" linkID="63346"&gt;BRAVO EXTENSION&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="25330"&gt;LAQ-5063OL&lt;/ulink&gt;  &lt;ulink linkType="Protocol" linkID="16575"/&gt;which evaluated the long-term efficacy of laquinimod were presented. Number of patients with &gt;/= 1 SAE, appendicitis, uterine leiomyoma, multiple sclerosis relapse, peritonitis, urinary tract infection, hysterectomy, fall, breast cancer, myocardial infarction, and cholelithiasis occured in 374, 15, 12, 11, 8, 8, 8, 7, 7, 6, and 6  patients  with event rate per 100 patient-years was 7.12, 0.16, 0.13, 0.12, 0.08, 0.08, 0.08, 0.07, 0.07, 0.06, and 0.06, respectively in LAQALL cohort and in 208, 7, 5, 3, 5, 4, 1, 6, 6, 2, and 2 patients with event rate per 100 patient-years was 6.33, 0.13, 0.09, 0.06, 0.09, 0.08, 0.02, 0.11, 0.11, 0.04, and 0.04, respectively in LAQ 2YR cohort. AEs with event rate of &amp;gt; 2/100 PY included number of patients with &gt;/= 1 AE, headache, nasopharyngitis, back pain, upper respiratory tract infection  (URTI), arthralgia, UTI, depression, influenza, and bronchitis with   occurence of  179.36, 10.03, 9.56, 6.57, 3.96, 3.04, 3.26, 2.27, 2.47, and 2.09 event rate per 100 patient-years, respectively in LAQALL cohort and 131.82, 5.38, 7.67, 5.21, 3.06, 2.13, 3.02, 1.92, 2.03, and 1.99 event rate per 100 patient-years, respectively in LAQ 2YR  cohort. The increased incidence of shifting to abnormal levels for alanine aminotransferase and aspartate aminotransferase seen with LAQ in the core studies was not observed in the LAQ 2YR cohort. There were no further changes (from the known pattern noted in the DBPC phase) in the mean values of CRP, fibrinogen, hemoglobin, WBC counts, or platelets reported with increased exposure [&lt;ulink linkType="Reference" linkID="1700539"&gt;1700539&lt;/ulink&gt;]. Similar results were presented in April 2015 [&lt;ulink linkType="Reference" linkID="1753534"&gt;1753534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pooled results presented in April 2016 also showed that percentage of patients with normal AST tests at baseline and at least one post-baseline measurement (&gt; 1 and &amp;lt;/= 3 x ULN; &gt;3 and &amp;lt;/= 5 ULN; &amp;gt; 5 and &amp;lt;/= 5 x ULN; &amp;gt; 8 x ULN) was 100% (16; &amp;lt; 1; &amp;lt; 1; &amp;lt; 1 respectively) for LAQALL group and 100% (5; &amp;lt; 1; &amp;lt; 1; 0 respectively) for LAQ 2YR group. Percentage of patients with normal AST tests at baseline and at least one post-baseline measurement (&gt; 1 and &amp;lt;/= 3 x ULN; &gt;3 and &amp;lt;/= 5 ULN; &amp;gt; 5 and &amp;lt;/= 5 x ULN; &amp;gt; 8 x ULN) was 100% (31; 2; &amp;lt; 1; &amp;lt; 1 respectively) for LAQALL group and 100% (11; &amp;lt; 1; &amp;lt; 1; &amp;lt; 1 respectively) for LAQ 2YR group. Percentage of patients with normal GGT tests at baseline and at least one post-baseline measurement (&gt; 1 and &amp;lt;/= 3 x ULN; &gt;3 and &amp;lt;/= 5 ULN; &amp;gt; 5 and &amp;lt;/= 8 x ULN; &amp;gt; 8 x ULN) was 100% (20; 3; &amp;lt; 1; &amp;lt; 1 respectively) for LAQALL group and 100% (14; &amp;lt; 1; &amp;lt; 1; &amp;lt; 1 respectively) for LAQ 2YR group [&lt;ulink linkType="Reference" linkID="1753534"&gt;1753534&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to make &lt;ulink linkType="Drug" linkID="25049"&gt;laquinimod&lt;/ulink&gt; 0.6 mg available for all patients who      completed the placebo-controlled &lt;ulink linkType="Protocol" linkID="6758"&gt;MS-LAQ-301&lt;/ulink&gt; study according to the protocol and to evaluate      the long-term safety, tolerability and effect on disease course of daily   laquinimod  po qd in patients with relapsing multiple sclerosis.&lt;/para&gt;&lt;para&gt;The objective of this study was to assess the effect of laquinimod treatment on disease course for patients treated for three years (early-start) and for patients originally treated with placebo and switched to laquinimod treatment for one year (delayed-start) in the open-label extension phase  [&lt;ulink linkType="Reference" linkID="1590643"&gt;1590643&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1590644"&gt;1590644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sub-Study:&lt;br/&gt;Ancillary studies described within the core protocol would be performed in a subset of patients:&lt;br/&gt;MRI: patients who participated in the Frequent MRI ancillary study during the MS-LAQ-301 study would be offered to continue to undergo MRI scans during the open-label extension study. During the MS-LAQ-301E study, these scans would be performed at Months 0E [Baseline (This was the Termination scan of the MS-LAQ-301 study)] and then every 12 months thereafter, until Termination/Early discontinuation.&lt;/para&gt;&lt;para&gt;Magnetization Transfer (MT): patients who participated in the MT ancillary study during the MS-LAQ-301 study would be offered to continue to undergo MT scans during the open-label&lt;br/&gt;extension study. During the MS-LAQ-301E study, these scans would be performed at Months 0E [Baseline (Termination visit of the MS-LAQ-301 study)] (this scan was a part of the MT ancillary&lt;br/&gt;study under the MS-LAQ-301 protocol) and then every 12 months thereafter until Termination/Early discontinuation.&lt;/para&gt;&lt;para&gt;Magnetic Resonance Spectroscopy (MRS): patients who participated in the MRS ancillary study during the MS-LAQ-301 study would be offered to continue to undergo MRS scans during the open-label extension study. During the MS-LAQ-301E study, these scans would be performed at Months 0E [Baseline (Termination visit of the MS-LAQ-301 study)] (this scan was a part of the MRS ancillary study under the MS-LAQ-301 protocol) and then every 24 months thereafter, until Termination/Early discontinuation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2012, results were published. The relapse rate of the early-start patients in the extension phase was 0.21, when compared to the 0.30 ARR observed during the placebo-controlled phase of the &lt;ulink linkType="Protocol" linkID="6758"&gt;ALLEGRO&lt;/ulink&gt; trial. After 12 months, the relapse rate of the delayed-start patients was 0.24 compared to the annualized relapse rate of 0.39 in the placebo-controlled &lt;ulink linkType="Protocol" linkID="6758"&gt;ALLEGRO&lt;/ulink&gt; trial [&lt;ulink linkType="Reference" linkID="1590643"&gt;1590643&lt;/ulink&gt;]. Similar results were published  [&lt;ulink linkType="Reference" linkID="1590644"&gt;1590644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, results were presented. The risk of confirmed disability progression was significantly smaller in early-start patients (11.8%) compared with delayed-start patients (16.7%; p &amp;lt; 0.0038) [&lt;ulink linkType="Reference" linkID="1394350"&gt;1394350&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1533475"&gt;1533475&lt;/ulink&gt;]. Similar results were published in August 2013 [&lt;ulink linkType="Reference" linkID="1462514"&gt;1462514&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, pooled results of &lt;ulink linkType="Protocol" linkID="6758"&gt;ALLEGRO&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="16575"&gt;BRAVO&lt;/ulink&gt;, and their on-going extensions ALLEGRO Extension      and &lt;ulink linkType="Protocol" linkID="63346"&gt;BRAVO Extension&lt;/ulink&gt; studies which evaluated the long-term efficacy of laquinimod were presented. Annualized relapse rate (ARR) remained low for the population.  ARR was 0.21 in delayed-start patients and 0.18 in early-start patients (reduced by 16.3%). A pronounced CDP treatment effect was observed for 6-month CDP (p = 0.0003) and 12-month CDP (p = 0.0082). The percentage of relapse-free patients at month 72 of follow-up was estimated to be 44.6% (early-start patients) and 39.3% (delayed-start patients) [&lt;ulink linkType="Reference" linkID="1700539"&gt;1700539&lt;/ulink&gt;].  Similar results were presented in April 2016 [&lt;ulink linkType="Reference" linkID="1753534"&gt;1753534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pooled results presented in April 2016 also reported that delayed start patients showed reduced ARR during the OL phase compared to placebo-controlled phase. Early-start patients showed lesser time to 6-month and 12-month CDP compared to delayed-start patients (p = 0.0929 and 0.0312, respectively). This effect was maintained throughout the OL phase [&lt;ulink linkType="Reference" linkID="1753534"&gt;1753534&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive laquinimod (0.6 mg, po, qd).&lt;/para&gt;&lt;para&gt;Safety and tolerability outcome measures:&lt;br/&gt;Safety: adverse events, vital signs, ECG findings and clinical laboratory parameters.&lt;br/&gt;Tolerability:&lt;br/&gt;Proportion of patients % who prematurely discontinued from the study, reason of discontinuation and the time to withdrawal.&lt;br/&gt;Proportion of patients % who prematurely discontinued from the study due to AEs and the time to withdrawal.&lt;/para&gt;&lt;para&gt;To assess the long-term effect of laquinimod 0.6 mg on disease course, as assessed by several parameters:&lt;br/&gt;Number of confirmed relapses.&lt;br/&gt;Progression of disability as measured by the EDSS score (including FS and AI).&lt;br/&gt;Progression of disability as measured by the MSFC score, Binocular low-contrast visual acuity using the 100, 2.5 and 1.25% contrast level charts (Sloan letter ) or Tumbling-E.&lt;br/&gt;Patient-reported fatigue as assessed by the Modified Fatigue Impact Scale (MFIS).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received 36 months (early-start) or 24 months of &lt;ulink linkType="Drug" linkID="25049"&gt;laquinimod&lt;/ulink&gt; (0.6 mg, po) treatment (delayed-start) [&lt;ulink linkType="Reference" linkID="1533475"&gt;1533475&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1700539"&gt;1700539&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="144671">laquinimod</Intervention><Treatments><Treatment><Dose>0.6 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name></Contact></Contacts></Site><Site><Name>Teva Investigational Site 3300</Name><Address1>Klagenfurt</Address1><Address3>9020</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3302</Name><Address1>St. Poelten</Address1><Address3>3100</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3303</Name><Address1>Linz</Address1><Address3>A-4021</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Bulgaria"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 5900</Name><Address1>Sofia</Address1><Address3>1606</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5901</Name><Address1>Pleven</Address1><Address3>5800</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5902</Name><Address1>Varna</Address1><Address3>9010</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5903</Name><Address1>Sofia</Address1><Address3>1309</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5904</Name><Address1>Sofia</Address1><Address3>1113</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5905</Name><Address1>Sofia</Address1><Address3>1606</Address3><Contacts/></Site><Site><Address2>Bulgarian Drug Agency</Address2><CountrySubDivision>Bulgarian Drug Agency</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Teva Investigational Site 1126</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 5A5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1128</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><Address3>K2G 6E2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1129</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H1T 2M4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1130</Name><Address1>Greenfield Park</Address1><Address2>Quebec</Address2><Address3>J4V 2J2</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1131</Name><Address1>Sherbrooke</Address1><Address2>Quebec</Address2><Address3>J1H 5N4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1132</Name><Address1>Bedford</Address1><Address2>Nova Scotia</Address2><Address3>B4A 1A9</Address3><CountrySubDivision>Nova Scotia</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1134</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M4N 3M5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 5416</Name><Address1>Ostrava - poruba</Address1><Address2>Czechia</Address2><Address3>708 52</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 5417</Name><Address1>Olomouc</Address1><Address2>Czechia</Address2><Address3>779 00</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 3236</Name><Address1>Hamburg</Address1><Address3>20246</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3237</Name><Address1>Emden</Address1><Address3>26721</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3238</Name><Address1>Berlin</Address1><Address3>13347</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3239</Name><Address1>Hannover</Address1><Address3>30171</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3240</Name><Address1>Erfurt</Address1><Address3>99089</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3241</Name><Address1>Berlin</Address1><Address3>10713</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3242</Name><Address1>Erbach</Address1><Address3>64711</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3243</Name><Address1>Heidelberg</Address1><Address3>69120</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3244</Name><Address1>Ulm</Address1><Address3>89081</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3245</Name><Address1>Dresden</Address1><Address3>01307</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3246</Name><Address1>Hamburg</Address1><Address3>22417</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3247</Name><Address1>Bayreuth</Address1><Address3>95445</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3248</Name><Address1>Bochum</Address1><Address3>44791</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3249</Name><Address1>Freiburg</Address1><Address3>79106</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3250</Name><Address1>Trier</Address1><Address3>54292</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3251</Name><Address1>Munster</Address1><Address3>48149</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Estonia"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 5504</Name><Address1>Tallinn</Address1><Address3>EE-10617</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5505</Name><Address1>Tartu</Address1><Address3>EE-51014</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts/></Site><Site><Name>Teva Investigational Site 3132</Name><Address1>Barcelona</Address1><Address3>08035</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3133</Name><Address1>Madrid</Address1><Address3>28040</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3134</Name><Address1>Barcelona</Address1><Address3>08036</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3135</Name><Address1>Lleida</Address1><Address3>25198</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3136</Name><Address1>Salt</Address1><Address3>17190</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3137</Name><Address1>Murcia</Address1><Address3>30120</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3138</Name><Address1>Pontevedra</Address1><Address3>36001</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3139</Name><Address1>Santiago de Compostela</Address1><Address3>15706</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3140</Name><Address1>Beade-Pontevedra</Address1><Address3>36312</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3142</Name><Address1>Getafe</Address1><Address3>28905</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3143</Name><Address1>Valencia</Address1><Address3>46010</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3144</Name><Address1>Barcelona</Address1><Address3>08041</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3146</Name><Address1>Madrid</Address1><Address3>28046</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site><Site><Name>Teva Investigational Site 3524</Name><Address1>Lille Cedex</Address1><Address3>59037</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3525</Name><Address1>Besancon</Address1><Address3>25030</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3526</Name><Address1>Clermont-Ferrand Cedex 1</Address1><Address3>63003</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3527</Name><Address1>Bron Cedex</Address1><Address3>69677</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3528</Name><Address1>Marseille Cedex 5</Address1><Address3>13385</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3529</Name><Address1>Rennes Cedex 9</Address1><Address3>35033</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>Teva Investigational Site 3422</Name><Address1>Sheffield</Address1><Address3>S10 2JF</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3424</Name><Address1>London</Address1><Address3>E1 2AT</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3425</Name><Address1>Liverpool</Address1><Address3>L9 7LJ</Address3><Contacts/></Site><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Georgia"><Sites><Site><Name>Teva Investigational Site 8100</Name><Address1>Tbilisi</Address1><Address3>0112</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 8101</Name><Address1>Tbilisi</Address1><Address3>0179</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 5114</Name><Address1>Debrecen</Address1><Address3>4043</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5115</Name><Address1>Budapest</Address1><Address3>H-1145</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5116</Name><Address1>Miskolc</Address1><Address3>3526</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5117</Name><Address1>Veszprem</Address1><Address3>H-8200</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Israel"><Sites><Site><Name>Teva Investigational Site 8030</Name><Address1>Jerusalem</Address1><Address3>9112001</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 8031</Name><Address1>Haifa</Address1><Address3>3436212</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 8032</Name><Address1>Tel Aviv</Address1><Address3>78278</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 8033</Name><Address1>Ramat Gan</Address1><Address3>5262160</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts/></Site><Site><Name>Teva Investigational Site 3038</Name><Address1>Milano</Address1><Address3>20132</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3039</Name><Address1>Milano</Address1><Address3>20148</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3040</Name><Address1>Rome</Address1><Address3>00133</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3041</Name><Address1>Palermo</Address1><Address3>90146</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3042</Name><Address1>Gallarate</Address1><Address3>21013</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3044</Name><Address1>Catania</Address1><Address3>95124</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3045</Name><Address1>Fidenza</Address1><Address3>43036</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3046</Name><Address1>Grosseto</Address1><Address3>58100</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 555</Name><Address1>Milano</Address1><Address3>20132</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Lithuania"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 5704</Name><Address1>Kaunas</Address1><Address3>50009</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5705</Name><Address1>Siauliai</Address1><Address3>76231</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 3809</Name><Address1>Nijmegen</Address1><Address3>6525 GC</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 3810</Name><Address1>Nieuwegein</Address1><Address3>3430 EM</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Name>Teva Investigational Site 5315</Name><Address1>Lodz</Address1><Address3>90-153</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5316</Name><Address1>Katowice</Address1><Address3>40-752</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5317</Name><Address1>Krakow</Address1><Address3>31-826</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5318</Name><Address1>Kielce</Address1><Address3>25-726</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5319</Name><Address1>Konskie</Address1><Address3>26-200</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5320</Name><Address1>Gorzow Wielkopolski</Address1><Address3>66-400</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5322</Name><Address1>Czestochowa</Address1><Address3>42-280</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5325</Name><Address1>Warszawa</Address1><Address3>04-749</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Romania"><Sites><Site><Name>Teva Investigational Site 5208</Name><Address1>Bucharest</Address1><Address3>011461</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5209</Name><Address1>Timisoara</Address1><Address3>300736</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5210</Name><Address1>Cluj-Napoca</Address1><Address3>400437</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5211</Name><Address1>Targu-Mures</Address1><Address3>540136</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5212</Name><Address1>Constanta</Address1><Address3>900123</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Serbia"><Sites><Site><Name>Teva Investigational Site 6100</Name><Address1>Belgrade</Address1><Address3>11000</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 6102</Name><Address1>Nis</Address1><Address3>18 000</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>Teva Investigational Site 5021</Name><Address1>Moscow</Address1><Address3>127015</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5022</Name><Address1>Saint Petersburg</Address1><Address3>197022</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5023</Name><Address1>St. Petersburg</Address1><Address3>197376</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5024</Name><Address1>St. Petersburg</Address1><Address3>194354</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5025</Name><Address1>St. Petersburg</Address1><Address3>194044</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5026</Name><Address1>St.Petersburg</Address1><Address3>191186</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5027</Name><Address1>Novosibirsk</Address1><Address3>630087</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5028</Name><Address1>Nizhny Novgorod</Address1><Address3>603126</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5029</Name><Address1>Ekaterinburg</Address1><Address3>620102</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5030</Name><Address1>Perm</Address1><Address3>614990</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information desk</Name></Contact><Contact type="Facility contact backup"><Email>info.era-clinical@teva.de</Email><Name>Clinical Trial Information desk</Name><Phone>000000000000</Phone></Contact></Contacts></Site><Site><Name>Teva Investigational Site 4204</Name><Address1>Stockholm</Address1><Address3>14186</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 4205</Name><Address1>Stockholm</Address1><Address3>17176</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 4206</Name><Address1>Stockholm</Address1><Address3>18288</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Turkey"><Sites><Site><Name>Teva Investigational Site 8201</Name><Address1>Izmir</Address1><Address3>35340</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Ukraine"><Sites><Site><Name>Teva Investigational Site 5800</Name><Address1>Lviv</Address1><Address3>79010</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5801</Name><Address1>Vinnytsya</Address1><Address3>21005</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5802</Name><Address1>Kyiv</Address1><Address3>03110</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5803</Name><Address1>Dnipropetrovsk</Address1><Address3>49027</Address3><Contacts/></Site><Site><Name>Teva Investigational Site 5804</Name><Address1>Kyiv</Address1><Address3>03115</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Teva Investigational Site 1073</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27157</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1075</Name><Address1>Lubbock</Address1><Address2>Texas</Address2><Address3>79410</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1076</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85004</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1078</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1081</Name><Address1>Fort Wayne</Address1><Address2>Indiana</Address2><Address3>46845</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1082</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1083</Name><Address1>Des Moines</Address1><Address2>Iowa</Address2><Address3>50314</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1084</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45417</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1085</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53215</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1086</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3>66103</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1088</Name><Address1>Fort Collins</Address1><Address2>Colorado</Address2><Address3>80528</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1090</Name><Address1>Centennial</Address1><Address2>Colorado</Address2><Address3>80112</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1092</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73120</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1093</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55414</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1096</Name><Address1>Farmington Hills</Address1><Address2>Michigan</Address2><Address3>48334</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1097</Name><Address1>Fargo</Address1><Address2>North Dakota</Address2><Address3>58103</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1098</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3>63104</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1100</Name><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3>17033-0850</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1101</Name><Address1>Lexington</Address1><Address2>Kentucky</Address2><Address3>40513</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 1102</Name><Address1>Northbrook</Address1><Address2>Illinois</Address2><Address3>60062</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry><Sites><Site><Name>Teva Investigational Site 5416</Name><Address1>Ostrava - poruba</Address1><Address2>Czechia</Address2><Address3>708 52</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 5417</Name><Address1>Olomouc</Address1><Address2>Czechia</Address2><Address3>779 00</Address3><CountrySubDivision>Czechia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Multiple sclerosis</Disease><PatientSegments><PatientSegment><PatientSegment id="128">Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00988052</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2009-012989-30</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Multiple sclerosis" id="2039"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Multiple sclerosis" id="2054">Safety laboratory parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Multiple sclerosis" id="2041"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Multiple sclerosis" id="2055"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Multiple sclerosis" id="45405"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Multiple sclerosis" id="2043">Assessment by echocardiography</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Multiple sclerosis" id="1794"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple sclerosis" id="1798"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple sclerosis" id="2039"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Multiple sclerosis" id="792"><Criterion>Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Multiple sclerosis" id="1234"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Multiple sclerosis" id="1249">Subjects on cytochromes</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-07-01T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>16.71 Months</EnrollmentPeriod><EnrollmentRate>50.21 Patients/Month</EnrollmentRate><DateFirstReceived>2009-09-28T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-10-06T08:45:49Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-09-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-01-11T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-01-11T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-01-11T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-01-11T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="removed"><Date>2019-01-11T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-01-11T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-01-11T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-01-11T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-01-11T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="62012"><TitleDisplay>To Evaluate the Blood Levels and Safety of iv and Subcutaneous CDP-6038 in Subjects With Rheumatoid Arthritis Using Methotrexate</TitleDisplay><TitleOfficial>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of iv and Subcutaneous CDP-6038 in Subjects With Rheumatoid Arthritis on a Stable Dose of Methotrexate</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">RA0010</Identifier><Identifier type="NCT">NCT01009242</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>olokizumab</Name><Drug id="61984">olokizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="61984">olokizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="20452">UCB SA</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="61984" type="Drug"><TargetEntity id="657216" type="siDrug">Olokizumab</TargetEntity></SourceEntity><SourceEntity id="20452" type="Company"><TargetEntity id="4295859381" type="organizationId">Ucb SA</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="20452">UCB SA</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="471">IL-6 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><PatientCountEvaluable>40</PatientCountEvaluable><DateStart>2009-10-31T00:00:00Z</DateStart><DateEnd type="actual">2010-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-05-22T04:25:23Z</DateChangeLast><DateAdded>2009-11-19T09:01:31Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>+1 877 822 9493 (UCB)</Affiliation><Name>UCB Clinical Trial Call Center</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;RA&amp;gt; 6 months duration on stable methotrexate&lt;/li&gt;&lt;li&gt;Swollen joints&amp;lt;/= 9, and tender joints &amp;lt;/= 9  (28 joint count)&lt;/li&gt;&lt;li&gt;Minimum screening CRP of 0.5 mg/l&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participation in previous studies with defined agents and durations&lt;/li&gt;&lt;li&gt;Previous treatment with defined agents and durations&lt;/li&gt;&lt;li&gt;Presence of, or history of defined medical conditions including those particularly             associated with deficiency in immune response&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Positive tests/signs of possible latent/active tuberculosis&lt;/li&gt;&lt;li&gt;Positive HIV&lt;/li&gt;&lt;li&gt;Drug addiction or alcohol abuse&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>PK/PD relationship between systemic CDP-6038 exposure and CRP suppression</Description><Timeframe>For 12 weeks following single dose</Timeframe></Measure><Measure><Description>Evaluate the safety and tolerability of single doses of CDP-6038 For 12 weeks following single dose</Description><Timeframe>For 12 weeks following single dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Absolute bioavailability of CDP-6038 given by sc injection in comparison with iv infusion</Description><Timeframe>For 12 weeks following single dose</Timeframe></Measure><Measure><Description>Assess the immunogenicity of single dose CDP-6038</Description><Timeframe>Multiple sampling from 0 to 12 weeks following single dose</Timeframe></Measure><Measure><Description>Assess, on an exploratory basis, changes in clinical response and other systemic biomarkers associated with RA</Description><Timeframe>For 12 weeks following single dose</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In November 2012, data were presented. Headache, infection, decreased WBC, and abnormal liver function tests were the commonly reported adverse events (AEs) and the severity, grade or frequency of these events had no relationship with the dose. One patient each in the placebo and   &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;   groups experienced serious AEs (Bowen's disease and worsening of RA [&lt;ulink linkType="Reference" linkID="1343246"&gt;1343246&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objectives were to determine the relationship between blood levels of &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt; and      suppression of C-reactive protein (CRP) following single doses given as iv infusion   or sc  injection to rheumatoid arthritis (RA) patients.  The safety      of &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt; would also be evaluated. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2012, data were presented from the pilot study at the ACR/ARHP Annual Meeting in Washington DC. Overall, 38 patients completed the 12-week follow-up. Following   &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;   administration (at all doses), the plasma CRP was suppressed in a dose-dependent manner (except at 0.1 mg/kg iv) and sustained until the end of study. The levels of IL-6 were suppressed markedly and this suppression sustained throughout the study duration.  Complement C3 and C4 reduced dose-dependently. The terminal plasma elimination half-life of   &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;   was consistent with both iv and sc routes, and was a median of 31 days. At the 1.0 and 3.0 mg/kg sc dose levels, the respective mean Cmax values were 6.29 and 19.1 micro/ml, achieved within a median Tmax of 13 and 7 days. The bioavailability of   &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;   based on the data pooled from this study and a first-in-human study was 76%, and was 66% based on the data from this study alone [&lt;ulink linkType="Reference" linkID="1343246"&gt;1343246&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of two cohorts:&lt;br/&gt;Cohort 1: group 1 would compare &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;, 0.1, 1 mg/kg and placebo iv and group 2 would compare &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;, 1 mg/kg and placebo sc. &lt;br/&gt;Cohort 2: group 3 would compare optimized sc doses of &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt; based on outcome of cohort 1 with placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 40) were randomized (1 : 3) to receive placebo or  &lt;ulink linkType="Drug" linkID="61984"&gt;CDP-6038&lt;/ulink&gt;  at doses of 0.1 or 1.0 mg/kg iv or 1 or 3 mg/kg sc [&lt;ulink linkType="Reference" linkID="1343246"&gt;1343246&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>olokizumab</Name><Drug id="61984">olokizumab</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="148">Headache</Indication></AdverseEvent><AdverseEvent><Indication id="291">Rheumatoid arthritis</Indication></AdverseEvent><AdverseEvent><Indication id="3720">Bowen disease</Indication></AdverseEvent><AdverseEvent><Indication id="680">Leukopenia</Indication></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="147968">olokizumab</Intervention><Treatments><Treatment><Dose>0.1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>1 milligram/kg</Dose><Route>Subcutaneous</Route></Treatment><Treatment><Dose>1 milligram/kg</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>3 milligram/kg</Dose><Route>Subcutaneous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Address1>Cologne</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Address1>Erlangen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Address1>Dallas</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Address1>San Antonio</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Address1>Duncansville</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="537">Subjects on Rheumatoid Arthritis Therapy</PatientSegment><SubSegments><SubSegment id="538">Methotrexate</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01009242</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4000">Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="4139"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4142">Assessment of serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="4243"><Endpoint>Assessment of Immune Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Rheumatoid arthritis" id="3999"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Rheumatoid arthritis" id="4002">Assessment of interleukins</SubEndpoint><SubEndpoint disease="Rheumatoid arthritis" id="4016">Complement System (CH50, C3, C4),</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rheumatoid arthritis" id="1900"><Criterion>Active Rheumatoid Arthritis</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1906">Active disease with swollen joint count</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1907">Active disease with tender joint count</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1931"><Criterion>Subjects on Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1932">Subjects on methotrexate (MTX)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="33268"><Criterion>Subjects with Abnormal Laboratory Parameters</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1908">Increased C-reactive protein (CRP) level</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2820"><Criterion>Subjects with Autoimmune/Immunological Disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2845"><Criterion>Subjects with History of Use of Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2846">Subjects with history of biological DMARDs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2919"><Criterion>Subjects with Immunodeficiency Disorders</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2921">HIV positive/AIDS subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2922"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2923">Subjects co-morbid with tuberculosis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2010-09-29T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>11.00 Months</EnrollmentPeriod><EnrollmentRate>3.64 Patients/Month</EnrollmentRate><DateFirstReceived>2009-11-04T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-11-19T09:01:31Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>